Your browser doesn't support javascript.
loading
Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a ß-Lactamase Inhibitor, in Healthy Subjects.
Lickliter, Jason D; Lawrence, Kenneth; O'Donnell, John; Isaacs, Robin.
Affiliation
  • Lickliter JD; Nucleus Network, Melbourne, Australia.
  • Lawrence K; Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA.
  • O'Donnell J; Entasis Therapeutics, Inc., Waltham, Massachusetts, USA John.odonnell@entasistx.com.
  • Isaacs R; Entasis Therapeutics, Inc., Waltham, Massachusetts, USA.
Antimicrob Agents Chemother ; 64(7)2020 06 23.
Article in En | MEDLINE | ID: mdl-32284380
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Beta-Lactamase Inhibitors / Anti-Bacterial Agents Type of study: Clinical_trials Limits: Aged / Humans Language: En Journal: Antimicrob Agents Chemother Year: 2020 Document type: Article Affiliation country: Australia Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Beta-Lactamase Inhibitors / Anti-Bacterial Agents Type of study: Clinical_trials Limits: Aged / Humans Language: En Journal: Antimicrob Agents Chemother Year: 2020 Document type: Article Affiliation country: Australia Country of publication: Estados Unidos